HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Friday, K. E. Search for Related Content PubMed PubMed Citation Articles by Friday, K. E.

---

MINIREVIEW

Aggressive Lipid Management for Cardiovascular Prevention: Evidence from Clinical Trials

Department Medicine, Tulane University Health Sciences Center, New Orleans, Louisiana 70112

Epidemiologic evidence shows that elevated serum cholesterol, specifically low-density lipoprotein cholesterol (LDL-C), increases the risk of coronary heart disease (CHD). Moreover, large-scale intervention trials demonstrate that treatment with HMG-CoA reductase inhibitors (statins), the most effective drug class for lowering LDL-C, significantly reduces the risk of CHD events. Unfortunately, only a moderate percentage of hypercholesterolemic patients are achieving LDL-C targets specified by the National Cholesterol Education Program (NCEP), in part because clinicians are not effectively titrating medications as needed to achieve LDL-C goals. Recent evidence suggests that more aggressive LDL-C lowering may provide greater clinical benefit, even in individuals with moderately elevated serum cholesterol levels. Furthermore, recent studies suggest that statins have cardioprotective effects in many high-risk individuals, including those with baseline LDL-C <100 mg/dl. High-density lipoprotein cholesterol (HDL-C) was recognized by the NCEP-Adult Treatment Panel II (ATP II) as a negative risk factor for CHD. The NCEP-ATP III guidelines have also reaffirmed the importance of HDL-C by increasing the low HDL-C designation from <35 to <40 mg/dl as a major risk factor for CHD. Similarly, triglyceride control will play a larger role in dyslipidemia management. As more clinicians effectively treat adverse lipid and lipoprotein cardiovascular risk factors, patients will likely benefit from reductions in cardiovascular events.

Key Words: coronary heart disease • cholesterol • statins • lipoproteins, LPL cholesterol • lipoproteins, HDL cholesterol

This article has been cited by other articles:

				A. P. Levine, D. P. Mikhailidis, T. Moross, K. Benson, and M. Gor Achieving Vascular Risk Factor Targets: A Survey of a London General Practice Angiology, March 1, 2008; 59(1): 36 - 46. [Abstract] [PDF]

				K. Ojala, E. Repo-Tiihonen, J. Tiihonen, and L. Niskanen Statins are effective in treating dyslipidemia among psychiatric patients using second-generation antipsychotic agents J Psychopharmacol, January 1, 2008; 22(1): 33 - 38. [Abstract] [PDF]